SLC5A2 and diabetes mellitus: As evidence for this, studies in HFrEF patients showed a lower risk of worsening heart failure or death from cardiovascular causes in patients receiving SGLT2, regardless of the presence or absence of diabetes, compared with those receiving the placebo [6,7].